Kezar Life Sciences, Inc. announced that Noreen Roth Henig, M.D., will be stepping down as Chief Medical Officer effective October 6, 2023. Zung To, SVP, Clinical Development Operations, will assume responsibilities for clinical trial execution and will oversee development operations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.84 USD | +3.11% | +1.88% | -11.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.34% | 61.15M | |
+10.44% | 107B | |
+0.82% | 106B | |
+8.59% | 23.47B | |
-13.89% | 21.9B | |
-6.03% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- KZR Stock
- News Kezar Life Sciences, Inc.
- Kezar Life Sciences, Inc. Announces Executive Changes